BioSpace News Archive

Alaunos Therapeutics, Inc. today announced that the Company will present at the 2nd Hawaii Global Summit on Thoracic Malignancies taking place June 27 – July 1, 2023.

Corvus Pharmaceuticals, Inc. today announced new preclinical data for ciforadenant, the Company’s adenosine 2A receptor inhibitor, highlighting its mechanism of action and synergy with immune checkpoint inhibitors via combination with anti-CTLA-4 and anti-PD-1 therapies.

Numinus Wellness Inc. will release its financial results for the quarter ended May 31, 2023, after market close on Monday, July 17, 2023.

HaemaLogiX Ltd today announced positive final results from a Phase IIb clinical study of its monoclonal antibody KappaMab in combination with lenalidomide and dexamethasone in kappa-type multiple myeloma patients who had relapsed or become refractory to other treatment options.

Ambrosia Bio today announced that Ambrosia Bio will leverage Ginkgo Enzyme Services, including its proprietary chassis organisms, to develop an expression strain for the scalable production of the Ambrosia Bio proprietary enzymes used for the conversion of feedstock into allulose.

Rallybio Corporation today announced that Stephen Uden, M.D., Rallybio’s President, Chief Operating Officer and Co-Founder has been appointed to the role of Chief Executive Officer, effective August 1, 2023.

Theratechnologies Inc. today announced it will report financial results and provide a business update for its second quarter ended May 31, 2023, on Wednesday, July 12 at 8:30 a.m. EDT.

Endo International plc (OTC: ENDPQ) announced today that Paladin Labs Inc., an Endo operating company, received Health Canada’s approval of XCOPRI ™ (cenobamate tablets) for adjunctive therapy in the management of partial-onset seizures in adults with epilepsy who are not satisfactorily controlled with conventional therapy.

Kyverna Therapeutics (“Kyverna”), a cell therapy company with the mission of engineering a new class of therapies for serious autoimmune diseases, today announced the enrollment of the first patient in its Phase 1 clinical trial of KYV-101 for the treatment of lupus nephritis (LN).

ZYUS Life Sciences Corp. is pleased to announce that Wayne Brownlee, former Vice-President and Chief Financial Officer (“CFO”) of both Potash Corporation of Saskatchewan Inc. (“PotashCorp”) and Nutrien Ltd. (“Nutrien”), has agreed to accept an appointment to ZYUS’ Board of Directors.